10-Q quarterly report · filed Nov 5, 2026

Inmune Bio, Inc. (INMB) Q3 2026 10-Q Quarterly Report

Short answer

Inmune Bio, Inc. (INMB) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026.

Q3 2026 key financials · XBRL

Net income
−$5M
+27.0% YoY · −270.9% QoQ
EPS (diluted)
−$0.17
+10.5% YoY · −240.0% QoQ

Source: XBRL data from the Inmune Bio, Inc. (INMB) Q3 2026 10-Q on SEC EDGAR. USD.

Inmune Bio, Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Q3 revenue $0, unchanged YoY; net loss $4.7M vs $6.5M
  • Q3 operating expenses $5.0M vs $7.4M, research and development $3.2M vs $4.9M
  • CORDStrom/INKmune costs $2.4M vs $1.1M, highest product-program spending
  • Cash $16.3M at September 30, 2026 vs $24.8M at December 31, 2025; operating cash use $10.0M
  • Near-term headwind: cash projected insufficient for one year; MAA targeted February 2027, BLA mid-2027

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Inmune Bio, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.